Mylan-Natco faces uphill battle in gaining market share from Teva#39;s MS drug

Mylan-Natco faces uphill battle in gaining market share from Teva#39;s MS drug
Mylan-Natco faces uphill battle in gaining market share from Teva#39;s MS drug Teva’s market share for Copaxone stood at 77-78 percent at the end of the quarter ended September